Business Wire

OR-OREGON-SYMPHONY

9.2.2021 19:17:04 CET | Business Wire | Press release

Share
Oregon Symphony Appoints David Danzmayr as New Music Director

The Oregon Symphony is proud to announce that acclaimed Austrian-born conductor David Danzmayr will serve as its next Music Director with the launch of its 2021-2022 season and the symphony’s 125th anniversary year. Regarded as one of today’s most gifted conductors, Danzmayr recently served as Chief Conductor of the Zagreb Philharmonic Orchestra and Music Director of ProMusica Chamber Orchestra. He has conducted orchestras at some of the world's most prominent concert halls in Germany, Italy, Scotland and major cities across the United States. Danzmayr follows esteemed Music Director Carlos Kalmar , who has held the position with the Oregon Symphony for the last 18 years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005045/en/

“We are thrilled to have David joining the Oregon Symphony as a creative leader with a unique artistic vision,” shares Scott Showalter, Oregon Symphony President and CEO. “His inaugural season, with the implementation of his Creative Alliance, reflects his desire to embrace wide-ranging cultures while inspiring and challenging audiences, and is sure to open another rich chapter in Oregon Symphony history.”

Danzmayr holds a strong belief that a composer’s musical expression is shaped by their personal environment, family heritage and culture, which will be reflected in the Symphony’s 2021-2022 season programming and launch of the Oregon Symphony Creative Alliance. Danzmayr’s vision unites a wide-range of musical innovators to create vibrant work from unique perspectives. Under Danzmayr, the Creative Alliance will feature extraordinary artists and cultural thought leaders, including Nathalie Joachim, Gabriela Lena Frank, Jun Märkl, Gabriel Kahane, Simone Lamsma and Johannes Moser.

“The Oregon Symphony is one of the county's top orchestras, with talented musicians and a passionate community, and I am honored to have been selected as its next Music Director,” says Danzmayr.” As part of my agenda, I’m committed to building upon the Symphony's high standard of excellence with music that is meaningful to Oregon audiences.”

Danzmayr will join the four-time Grammy-nominated Oregon Symphony for its pivotal 125th anniversary, marking a profound milestone as the Symphony continues its legacy as the oldest orchestra in the Western United States.

"Oregon is proud to share 125 years with our beloved Oregon Symphony, and I want to personally welcome David Danzmayr as its new Music Director,” says Gov. Kate Brown. “The Oregon Symphony is one of our state’s artistic treasures, and the last 18 years with Carlos Kalmar as Music Director have been phenomenal. I can't wait to see what the symphony achieves under David’s leadership."

The Oregon Symphony will announce its 2021-2022 season in March 2021. For information about David Danzmayr, visit www.orsymphony.org/Danzmayr .

About Oregon Symphony

Led by Music Director Carlos Kalmar, the Oregon Symphony serves more than 235,000 people annually through concerts and award-winning education and community programs. The Symphony continues to innovate through series such as SoundSights, Sounds of Home and SoundStories. Follow the Oregon Symphony on Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/OregonSymphony

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye